FDA Approves CELLCEPT — Genentech, Inc.

Genentech, Inc. announced the approval of CELLCEPT (mycophenolate mofetil) oral suspension, providing clinicians with a critical liquid formulation to treat severe immunosuppression in pediatric transplant patients. This launch holds significant commercial potential, as it expands the market accessibility of mycophenolate mofetil into specific pediatric demographics previously in need of alternative suspensions.